Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells Journal Article
| Authors: | Macgrogan, D.; Kalakonda, N.; Alvarez, S.; Scandura, J. M.; Boccuni, P.; Johansson, B.; Nimer, S. D. |
| Article Title: | Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells |
| Abstract: | The human L3MBTL gene is located in 20q 12, a region that is commonly deleted in myeloproliferative disorders (MPD), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). L3MBTL is highly homologous to the D-lethal(3) malignant brain tumor [D-1(3)mbt] gene, which is a putative tumor-suppressor gene (TSG) identified in Drosophila and which is closely related to the Drosofihiia sex combs on midleg (SCM) protein, a member of the Polycomb group (PcG) family of transcriptional repressors. To examine whether L3MB7L functions as a "classic" TSG in human hematologic malignancies, we screened a panel of 17 myeloid leukemia cell lines and peripheral blood or bone marrow samples from 29 MDS and 13 MPD patients for mutations in the entire L3MBTL coding sequence, including intron/exon splice junctions. No mutations were identified, although two single nucleotide differences were found (in intron 14 and in exon 15), which were interpreted as polymorphic changes. We used real-time RT-PCR to quantify the level of L3MBTL mRNA in various normal myeloid and lymphoid cell populations. L3MBTL is expressed in normal CD34+ bone marrow cells, and we found that the pattern of L3MBTL expression was similar to that of BMII, a well-studied PcG gene with oncogenic activity, suggesting that L3MBTL and BMII may be co-regulated during hematopoiesis. The expression of L3MBTL mRNA in 30 of 35 cell lines and 13 of 15 AML samples was comparable to the level of L3MBTL expression in the normal cell populations. However, five leukemia cell lines showed no L3MBTL expression, and two of the AML samples showed aberrant L3MBTL expression. These data suggest that L3MBTL is not mutated in MDS or MPD. However, given the known dosage effects of PcG proteins in regulating gene expression, reduced or absent L3MBTL expression may be relevant in some cases of myeloid leukemia. © 2004 Wiley-Liss, Inc. |
| Keywords: | controlled study; myeloproliferative disorders; unclassified drug; acute granulocytic leukemia; human cell; exon; gene deletion; mutation; myeloproliferative disorder; exons; polymerase chain reaction; gene; bone marrow cells; reverse transcription polymerase chain reaction; bone marrow; neoplasm proteins; intron; cell population; cell line, tumor; carcinogenesis; rna; gene expression regulation; tumor suppressor gene; hematologic malignancy; myelodysplastic syndrome; dna; messenger rna; blood sampling; reverse transcriptase polymerase chain reaction; screening; nucleotide sequence; leukemia, myeloid; hematopoietic cell; hematopoietic stem cells; real time polymerase chain reaction; dna mutational analysis; dna primers; gene dosage; loss of heterozygosity; protein family; repressor protein; antigens, cd34; gene location; myelodysplastic syndromes; leukemia cell line; gene structure; drosophila protein; chromosome 20q; dna, complementary; nucleotide; sequence analysis, dna; myeloid leukemia; lymphoid cell; polymorphism, single-stranded conformational; humans; human; priority journal; article; scm protein; bmi1 gene; dl3mbt gene; l3mbtl gene; pcg gene |
| Journal Title: | Genes Chromosomes and Cancer |
| Volume: | 41 |
| Issue: | 3 |
| ISSN: | 1045-2257 |
| Publisher: | Wiley Periodicals, Inc |
| Date Published: | 2004-11-01 |
| Start Page: | 203 |
| End Page: | 213 |
| Language: | English |
| DOI: | 10.1002/gcc.20087 |
| PROVIDER: | scopus |
| PUBMED: | 15334543 |
| DOI/URL: | |
| Notes: | Genes Chromosomes Cancer -- Cited By (since 1996):25 -- Export Date: 16 June 2014 -- CODEN: GCCAE -- Molecular Sequence Numbers: GENBANK: NT_011362; -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work